skip to content
Primary navigation


Drug Nulojix (belatacept) [BMS] 

February 2013

Therapeutic area - Immunosuppression

Approval criteria

  • Patient has received a kidney transplant AND
  • Patient is EBV seropositive

Background information

NULOJIX is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. Use is only approved in patients who are EBV seropositive and kidney transplant. 


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top